Table 5.

Univariable and Multivariable Cox Proportional Hazards for OS of Patients With Low-Grade Serous Carcinoma of Ovary or Peritoneum Treated With Primary Cytoreductive Surgery Followed by Platinum-Based Chemotherapy (n = 287)

Variable	Univariable			Multivariable
	HR	95% CI	P	HR	95% CI	P
Age, years
≤ 35 (reference)	—	—		—	—
> 35	0.51	0.37 to 0.71	< .001	0.55	0.39 to 0.79	.001
Race
White (reference)	—	—
Nonwhite	0.83	0.54 to 1.26	.37
Parity*
Nulliparous (reference)	—	—
Parous	0.85	0.60 to 1.19	.34
Smoking history†
Never (reference)	—	—
Ever	0.89	0.64 to 1.24	.48
BMI, kg/m2‡			.88
Normal (reference)	—	—
Overweight	1.07	0.61 to 1.87	.82
Obese	0.91	0.53 to 1.59	.75
Pretreatment CA-125§
< 35 (reference)	—	—
> 35	1.21	0.68 to 2.17	.52
FIGO stage
II (reference)	—	—
III to IV	1.16	0.53 to 2.52	.71
Site
Ovary (reference)	—	—		—	—
Peritoneal	0.55	0.34 to 0.88	.01	0.59	0.36 to 0.98	.04
Residual disease (primary CRS)‖
No gross residual (reference)	—	—
Gross residual	1.09	0.72 to 1.66	.69
Chemotherapy
Adjuvant chemotherapy (reference)	—	—
Chemotherapy (any) plus hormonal therapy	0.52	0.13 to 2.10	.36
Maintenance			.03
None or missing information (reference)	—	—
Hormonal therapy	1.05	0.64 to 1.73	.86
Chemotherapy	1.72	1.19 to 2.48	.004
Chemotherapy plus hormonal therapy	1.38	0.64 to 2.98	.42
Disease status at completion of primary treatment¶
NED (reference)	—	—		—	—
Disease present	2.02	1.44 to 2.85	< .001	1.99	1.41 to 2.81	< .001

Abbreviations: BMI, body mass index; CA-125, cancer antigen 125; CRS, cytoreductive surgery; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; NED, no evidence of disease; OS, overall survival.

^*Missing for two patients.

^†Not available for one patient.

^‡Not available for 112 patients.

^§Not available for 103 patients.

^‖Missing for 51 patients.

^¶Not available for 33 patients.